Pharmaceutical composition of baicalein and 10-hydroxycamptothecin and its application

A technology of hydroxycamptothecin and baicalein, which is applied in the direction of drug combinations, medical preparations containing active ingredients, antineoplastic drugs, etc., to achieve the effects of improving curative effect, reducing drug dosage, and significant synergistic effects

Active Publication Date: 2016-01-27
DALIAN UNIV OF TECH
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] So far, there is no report about the combined use of 10-hydroxycamptothecin and baicalein in anti-tumor and the synergistic effect of the two in anti-tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition of baicalein and 10-hydroxycamptothecin and its application
  • Pharmaceutical composition of baicalein and 10-hydroxycamptothecin and its application
  • Pharmaceutical composition of baicalein and 10-hydroxycamptothecin and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] (1) Dilute baicalein and 10-hydroxycamptothecin with the DMEM high-sugar culture medium containing 10% fetal bovine serum, 100kU / L penicillin, and 100mg / L streptomycin respectively to be the concentrations of Table 1~3, different The experimental results of the inhibitory effect on MCF7 proliferation when the concentration of baicalein and 10-hydroxycamptothecin are used alone are shown in figure 1 And Table 1 and Table 2.

[0047] Table 1 Calculation of baicalein in different dosages of MCF7 cell survival relationship parameters

[0048]

[0049] Table 210-Hydroxycamptothecin MCF7 cell survival relationship parameter calculation under different dosages

[0050]

[0051]

[0052] Taking Table 1 as an example for calculation and description, first obtain the survival rate of baicalein acting on MCF7 cells, and then perform fitting according to the relationship between the dosage and the cell survival rate to obtain the equation Y=4.96X-9.81, then b= 4.96, a=-9...

Embodiment 2

[0072] (1) Dilute baicalein and 10-hydroxycamptothecin with the DMEM high-glucose medium containing 10% fetal bovine serum, 100kU / L penicillin, and 100mg / L streptomycin respectively to be the concentrations of Table 4-6, different concentrations The experimental results of the inhibitory effect of baicalein and 10-hydroxycamptothecin on the proliferation of BGC823 can be found in image 3 And Table 4 and Table 5.

[0073] Table 4 Calculation of the BGC823 cell survival relationship parameters of baicalein at different dosages

[0074]

[0075] Table 510-Hydroxycamptothecin BGC823 cell survival relationship parameter calculation under different dosages

[0076]

[0077]

[0078] Similarly, the relationship between the theoretical dosage of baicalein and the cell survival rate is deduced as follows:

[0079] D. 单1 =Dm(fa / fu) 1 / m =159.04[(1-fu) / fu)] 1 / 5.57

[0080] The relationship between the theoretical dosage of 10-hydroxycamptothecin and the cell viability is: ...

Embodiment 3

[0090] (1) Dilute baicalein and 10-hydroxycamptothecin with the DMEM high-glucose medium containing 10% fetal bovine serum, 100kU / L penicillin, and 100mg / L streptomycin respectively to be the concentrations of Table 7-9, different concentrations The experimental results of the inhibitory effect of baicalein and 10-hydroxycamptothecin on the proliferation of SMMC7721 can be found in Figure 5 And Table 7 and Table 8.

[0091] Table 7 Calculation of baicalein in SMMC7721 cell survival relationship parameters under different dosages

[0092]

[0093]

[0094]Table 810-Hydroxycamptothecin SMMC7721 cell survival relationship parameter calculation under different dosages

[0095]

[0096] Similarly, the relationship between the theoretical dosage of baicalein and the cell survival rate is deduced as follows:

[0097] D. 单1 =Dm(fa / fu) 1 / m =107.37[(1-fu) / fu)] 1 / 2.61

[0098] The relationship between the theoretical dosage of 10-hydroxycamptothecin and the cell viability...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine composition which contains 10-hydroxycamptothecine and baicalein. The medicine composition has obvious synergetic effects on treating stomach cancer, breast cancer, liver cancer and the like, reduces the dose of the medicine, improves the curative effect of the medicine, and reduces the generation of side effects.

Description

technical field [0001] The present invention relates to an antitumor pharmaceutical composition, in particular to a pharmaceutical composition of baicalein and 10-hydroxycamptothecin and its preparation for treating lung cancer, pancreatic cancer, colon cancer, liver cancer, prostate cancer, kidney cancer, gastric cancer, brain cancer, etc. Use in drugs for tumors, sarcomas, ovarian or breast cancer. Background technique [0002] Cancer is one of the major diseases threatening human health. According to the World Health Organization, cancer has caused 7.6 million deaths in 2008 (accounting for about 13% of all deaths), and the number of deaths will continue to rise, and it is expected to exceed 13.1 million by 2030. Furthermore, most cancer deaths are caused by cancers of the lung, stomach, liver, colon and breast. Currently, there are three main methods for cancer treatment, namely surgery, radiotherapy and chemotherapy, among which chemotherapy is the main method. Howev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4745A61P35/00A61K31/352
Inventor 包永明唐琴王静云郝文博李莹雪姜波安利佳
Owner DALIAN UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap